PDF电子书：分子疗法（2011）

tianzhang

$ Z" w9 O/ T# q
' s5 E: Y) @7 d
Molecular therapies
* O2 t: N6 F' d* mDr. Zoltán Balajthy, Dr. János Aradi, Dr. Zoltán Balajthy, Dr. Éva Csősz, Dr. Beáta Scholtz, Dr. István Szatmári, Dr. József Tőzsér, Dr. Tamás Varga (2011)$ Q! |* G& i; P( u

4 L3 D( s, v* I; X3 v  i/ Y: cUniversity of Debrecen# u7 g6 T% r4 F4 L, [- x3 w% ?2 @. y1 Y
Copyright © 2011 The project is funded by the European Union and co-financed by the European Social Fund., Manuscript completed: 17 November 2011
+ ^" Y& v" Q& G
0 G3 B0 `2 h8 m# q2 |3 K. v0 E' V
! F  c5 A* t2 f+ D
Index) `" l; _& Q5 C) K! U0 C  Q. x! ?
1. 1. Functional Genomics, i( t8 Y; e, o" u' x6 }# d
1.1 Definitions
  H( h  u1 v( J8 ^& }0 F1.2 About diseases6 B" A* Q. k5 d, k( a& E5 o, P
1.3 Approaches to understanding disease mechanisms3 H5 D0 f8 U7 p7 i% n% C+ P/ b
1.3.1 Gene expression is regulated in several basic ways( q0 F6 T( w% b, i
1.3.2 Microarrays: functional genomics in cancer research
/ Q$ r. i9 C+ x2 V6 W5 {1.3.3 A Variety of Genetic Alterations Underlie Developmental Abnormalities and Disease
$ O- E2 v. ~% g0 f1.3.4 Genomic microarrays8 M# E  g. D& h6 V' i" R
2. 2. Recombinant proteins
0 R4 }6 _' J/ s$ t4 V! A8 k2.1 Overview: Protein pharmaceuticals. |0 l. e9 ]0 u' O
2.2 Cell-free systems: In vitro transcription and translation  v) s6 l6 V! N( P- A
2.3 Recombinant protein expression in isolated cells (cell culture)9 {. V7 b1 `; L5 x
2.4 Non-prokaryotic expression systems
7 \% A! s3 M6 i# Z" C2.4.1 Cloning in Pichia pastoris
# ~' m/ R  Y) V$ o2.4.2 Baculovirus mediated protein expression in insect cells8 |$ z( o' N, v0 w$ L
2.4.3 Mammalian expression systems0 l0 l- B& e( I3 {7 N
2.5 Purification of recombinant proteins5 z/ Q' c6 p# j9 z, s) V; e" b
3. 3. Gene Therapy: Vectors and Strategies.
; {! G/ s$ ?0 l4 a/ r% y% W  J3.1 Vectors for Gene Therapy
% W. {+ U5 o+ @& Y2 p3.2. Types of gene transfer, vectors for gene therapy
! q7 X0 e& q2 |% b$ ]3.3. General gene therapy strategies9 N( E4 H- F2 E5 v& Q- E
3.4. Human gene therapy' d( D6 e/ r% e$ {
4. 4. Protein replacement therapies.
* k7 I' D1 a9 R" |7 Y5. 5. Recombinant antibodies and the phage display technology+ p! r- b) ?5 P5 p* A" D$ S% f
5.1. Introduction  _, G" f- k1 _, L7 @0 p) O' v
5.1.1. The structure of antibodies and their production in the body
; j* e* W, @/ C$ |7 E6 A' S5.1.2. Antigen-antibody binding0 v7 D+ _2 m0 @4 O
5.2. The production of therapeutic antibodies$ M5 V/ R' r9 n, i& i
5.2.1. The production of antibodies in hybridoma cells.9 R" _7 P- U6 [" O! }, p
5.2.2. Humanized antibodies
' n9 k- E$ z4 @' V' T# D0 y" ]6 R: ~! f5.2.3. Production of human antibodies
5 u6 Y. X( x6 Z8 Q7 D4 |" \) ?5.3. Generation of antibodies by phage display
( P/ S) X" G- T4 I8 Q" }5.3.1. The phage display technology8 `0 x$ M/ Q  s( G- ?' b* V
5.3.2. Generation of phage libraries# m  k0 s1 f% F* g* b% s; G
5.4. Administration of therapeutic antibodies
. i  h& X$ m$ f6. 6. Anti-cytokine Therapy (sepsis).1 S* Q$ ?6 B7 b2 @( [% A
6.1. The consequences of developing inflammation0 g/ \4 k1 n5 i. m
6.2. Development of Inflammatory Response: Synthesis of Lipid Mediators
7 X6 K/ ]3 {7 b, v6.3. Role of the Liver in Maintenance of Homeostasis: Acute Phase Response( M+ e# v5 ]; \( v; _
6.4. Time-Course of the Inflammatory Response During Sepsis
0 |6 e' i  _( r3 l7. 7. Animal models and transgenesis in biotechnology) R  r/ I& X/ h3 a! W" W8 _2 v5 H
8. 8. Embryonic and adult stem cells in regenerative medicine I." I* ?  \4 t6 M2 Z! p& S% p
8.1 Embryonic stem cells1 N: U# L: ~* v2 o
8.2 Somatic cell reprogramming into pluripotent stem cells
; L) `) b  g) g3 n, g8 B% M8.3 Adult stem cells
0 Q* s" `; p% M6 X6 {% _* F9. 9. Embryonic and adult stem cells in regenerative medicine II.
! k" Z# G; a: q5 @( D9.1 Pluripotent stem cells for regenerative medicine
. X  E$ V! H7 j6 T0 m* T9.2 Clinical application of stem cells
7 u9 ]$ r6 P% q, |0 `4 r' r' |+ g- ~9.3 Stem cell therapy to cure various diseases
+ a* `: e: t/ i  s10. 10.        Cell Cycle and Cancer Therapy, p53 I.
- I6 Y# [. Y% j! s% w, ~, l10.1 Cell Cycle
  L( i+ o/ Y. i! Y10.2. Mitogenic Signaling in Eukaryotic Cell Controls the Rate of Cell Division
+ d2 y4 H% k- g% J) E. D10.3. Biochemical Events of Cell-cycle – in M Phase. Y' ?! W" o" a( v! a
10.4. Protooncogenes! d# {. T% K- E, f+ u
10.5. ErbB/HER Receptors* Y2 c" a  `% a5 u
10.6. Therapeutic targets, }" M9 j( ?& u+ @# J/ X1 z5 n
11. 11. Cell Cycle and Cancer Therapy, p53 II.
2 v  c! x; e' h) n11.1. Tumor Suppressor Genes and p53
) |$ o) B0 @7 Y% v5 {11.2. Biochemical Pathways of Apoptosis and its Therapeutic Utilization/ d" J. V6 N% j7 J, h/ r1 b
12. 12. Gene Silencing Technologies./ b  U; A4 `# }* z0 v/ P
12.1 Introduction
- ~1 f) v3 h; P; h* n12.2 Action of antisense oligonucleotides3 [8 A3 l( ~  F8 X/ j& F, W1 P
12.3 Chemical modifications of gene silencing oligonucleotides; general considerations
/ O4 B3 N0 V; t4 @# |8 j6 V0 a1 F12.4 Inhibition of transcription by triple helix forming oligonucleotides
8 ?2 f& v4 j) H: |12.5 Gene silencing by ribozymes+ h: X9 k5 t! M$ {: h+ {
12.6 Gene silencing with short RNA fragments
/ k! C- b- m* A& ~' C- h12.7 Important final note9 L$ f- n5 y; Z
2 t" q( W# m7 i. m" w' w. d( c
[hide][/hide]

mzaq2006

看看

mzaq2006

无法下载啊，扣了24个包包都不行

mzaq2006

是32个包包啊

goblinwang

学习学习

goblinwang

呵呵，我可以下载，估计，你不是使用网页自带的下载吧，记得以前论坛提起，尽量不用迅雷等下载软件，你在试试吧

xylan327

谢谢分享

xuguofeng

肌源性干细胞

石头111

干细胞研究重在基础

MIYAGI

嘿嘿......哈哈......呵呵.....哟~呼